Understanding The Potential Drug Target KCTD18 (G130535)

Target Name: KCTD18

NCBI ID: G130535

KCTD18

Other Name(s): 6530404F10Rik | Potassium channel tetramerization domain containing 18, transcript variant 1 | KCTD18 variant 1 | BTB/POZ domain-containing protein KCTD18 (isoform 1) | KCD18_HUMAN | potassium channel tetramerization domain containing 18 | potassium channel tetramerisation domain containing 18 | BTB/POZ domain-containing protein KCTD18

Understanding The Potential Drug Target KCTD18

KCTD18 (6530404F10Rik), a protein found in human placenta, has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer, neurodegenerative disorders, and immune-related conditions. Its unique structure and function make it an attractive target for researchers to explore.

The protein KCTD18 is a member of the KCTD18 family, which is known for its role in cell-signaling pathways. KCTD18 is expressed in various tissues and organs, including the placenta, brain, and heart. Its function is not yet well understood, but studies have shown that it plays a crucial role in the development and maintenance of normal placenta function.

One of the key functions of KCTD18 is its role in the formation of tight junctions, which are a type of cell-cell barrier that helps to maintain the integrity of tissues. tight junctions are also involved in the regulation of ion and solute transport, as well as the maintenance of electrical properties within cells.

In addition to its role in tight junction formation, KCTD18 has also been shown to play a role in the regulation of cell-cycle progression. It has been shown to promote the G1 phase of the cell cycle and the G2 phase of the cell cycle, which are important for cell growth and division.

The potential benefits of targeting KCTD18 as a drug target are numerous. If successful, it could lead to the development of new treatments for a variety of diseases. For example, KCTD18 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. By targeting this protein, researchers could potentially develop new treatments for these cancers.

In addition to its potential use as a cancer treatment, KCTD18 has also been identified as a potential biomarker for a variety of diseases. Its role in the regulation of cell-cycle progression and tight junction formation makes it an attractive target for the development of new diagnostic tests for a variety of conditions. For example, KCTD18 has been shown to be elevated in the blood of patients with various neurological disorders, including Alzheimer's disease and Parkinson's disease.

The identification of KCTD18 as a potential drug target and biomarker is an exciting development in the field of disease research. Further studies are needed to fully understand its function and potential as a drug target and biomarker. By doing so, researchers hope to develop new treatments for a variety of diseases and improve the quality of life for those affected by these conditions.

Protein Name: Potassium Channel Tetramerization Domain Containing 18

The "KCTD18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets